Spiro Jon, Venugopal Vinod, Raja Yogesh, Ludman Peter F, Townend Jonathan N, Doshi Sagar N
Interventional Cardiology Department, Queen Elizabeth Hospital Birmingham, Edgbaston, Birmingham, United Kingdom, B15 2WB.
Catheter Cardiovasc Interv. 2015 May;85(6):981-9. doi: 10.1002/ccd.25355. Epub 2014 Jan 31.
Assessment of the feasibility and outcomes of the 2.5 L and 3.8 L Impella cardiac pump in patients with severe aortic stenosis (AS) and left ventricular impairment undergoing percutaneous revascularization (PCI) with or without balloon aortic valvuloplasty (BAV).
We reviewed the clinical and procedural findings from a consecutive series of unselected patients with severe AS who underwent PCI during Impella support. In addition, we describe novel "balloon-assist" techniques that allowed implantation of Impella into the left ventricle (LV) when initial unassisted attempts failed.
Five patients with severe AS were identified (four males, age 78.2 years, aortic valve area (AVA) 0.6 cm(2) , left ventricular ejection fraction (LVEF) 24 ± 5%, mean Society of Thoracic Surgeons (STS) mortality 11% (range 3-17%)). The Impella catheter traversed the aortic valve (AV) unassisted in only one patient, with four cases requiring balloon-assist techniques. All patients underwent planned revascularisation; mean procedure time 177 min (range 135-252 min), mean number of stents 3.4 (range 1-8), with three patients requiring rotational atherectomy. All procedures were well tolerated, with absence of arrhythmia, hypotension, pulmonary edema, stroke, or myocardial infarction. One patient died 48 hr post-PCI of multi-organ failure. The four remaining patients were well at 30 days.
Implantation of the 2.5 and 3.8 L Impella appears feasible in patients with severe AS and left ventricle (LV) impairment. A balloon-assist technique may be used to facilitate device implantation when initial unassisted attempts fail. Improved hemodynamic stability may enhance the tolerability of lengthy and complex procedures.
评估2.5L和3.8L Impella心脏泵在重度主动脉瓣狭窄(AS)且左心室功能受损的患者中,接受或未接受球囊主动脉瓣成形术(BAV)的经皮血管重建术(PCI)的可行性及结果。
我们回顾了一系列连续入选的重度AS患者在Impella支持下接受PCI的临床及操作结果。此外,我们描述了一种新的“球囊辅助”技术,该技术可在最初未辅助尝试失败时将Impella植入左心室(LV)。
确定了5例重度AS患者(4例男性,年龄78.2岁,主动脉瓣面积(AVA)0.6cm²,左心室射血分数(LVEF)24±5%,胸外科医师协会(STS)平均死亡率11%(范围3 - 17%))。仅1例患者在未辅助的情况下Impella导管穿过主动脉瓣(AV),4例需要球囊辅助技术。所有患者均接受了计划的血管重建;平均手术时间177分钟(范围135 - 252分钟),平均支架数量3.4个(范围1 - 8个),3例患者需要旋磨术。所有手术耐受性良好,未出现心律失常、低血压、肺水肿、中风或心肌梗死。1例患者在PCI术后48小时因多器官衰竭死亡。其余4例患者在30天时情况良好。
对于重度AS和左心室(LV)功能受损的患者,植入2.5L和3.8L Impella似乎是可行的。当初始未辅助尝试失败时,可使用球囊辅助技术促进装置植入。改善的血流动力学稳定性可能会提高冗长复杂手术的耐受性。